• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Alnylam’s Market Cap Slashed 50 Percent

    Chelsea Pratt
    Oct. 07, 2016 03:46AM PST
    Biotech Investing
    Biotech Investing

    Poor clinical trial results never signal great things for a company’s stock, but rarely do they trigger a 50 percent slash in its market cap valuation.

    Poor clinical trial results never signal great things for a company’s stock, but rarely do they trigger a 50 percent slash in its market cap valuation. That’s what happened to Alnylam Pharmaceuticals (NASDAQ:ALNY), after the company cancelled an ongoing clinical trial for its product candidate, revusiran.
    On October 5, 2016, Alnylam had a market cap of six billion dollars. Today, that number has dropped to just over three billion. Share price has seen a dramatic depreciation, plummeting over 45 percent in just a few days—in fact, Alnylam was Thursday’s largest premarket decline.
    The drop stems from a single company announcement: Alnylam stopped a clinical trial for its product candidate, revusiran.The therapy was intended to treat hereditary ATTR amyloidosis with cardiomyopathy, a rare disease with few available treatment options. As such, many investors were excited about its potential to disrupt the market.
    But over the course of revusiran’s clinical trials, 18 patients died and there was evidence of nerve damage in other participants.


    It is difficult to say for certain whether those 18 fatalities resulted from the therapy or the condition itself. Nevertheless, the ENDEAVOUR Data Monitoring Committee (DMC) found a higher mortality rate in participants receiving revusiran versus those receiving the placebo. As a result, they recommended that all dosing be suspended, and the company has complied.
    “Patient safety comes first,” said CEO John Maragnore. In a press release issued on October 5, 2016, the company assured shareholders that this move would not affect development of patisiran, another therapy currently in phase III trials, or anything else in their pipeline.
    Yet the significant stock movement seems to indicate investor unease.
    That may be because Alnylam develops all of its products around a technology known as RNA interference—a way to turn select genes ‘on’ or ‘off.’ In theory, this approach has the potential to rapidly cure any number of medical conditions. “It’s like a whole factory. You just put in a different code and you pump out the drugs and you cure another disease,” explained Breakingviews columnist Robert Cyran.
    But the failure of revusiran seems to have generated anxiety over RNA interference itself. “The technology has had a lot of problems over the years with delivery and efficacy,” Cyran went on to note, “and it seems like this is another example of that problem.”
    Indeed, Alnylam’s major losses in the last few days suggest that investors are nervous about the potential of this technology going forward. With other gene-editing tools in development, they may be looking at different options in the space.

    Don’t forget to follow us @INN_LifeScience for real-time news updates.
    Securities Disclosure: I, Chelsea Pratt, hold no direct investment interest in any company mentioned in this article.
    rare diseaseproduct candidateclinical trialsphase iiiphase iii trialschelsea prattclinical trial resultsgene editing
    The Conversation (0)
    Go Deeper
    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    RAD receives IND approval from US FDA for Betabart (RV-01)

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×